Acute Interstitial Nephritis in a Patient With BRAF V600E Mutant Non-small Cell Lung Cancer Treated With Dabrafenib and Trametinib

This publication has 18 references indexed in Scilit:

• Granulomatous hepatitis: Is it bugs, drugs, or other untoward culprits?
  Clinical Liver Disease, 2024
• Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma – A case report and review of the literature
  Acta Clinica Belgica, 2022
• Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib
  Nephrology Dialysis Transplantation, 2020
• Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
  New England Journal of Medicine, 2019
• Understanding and targeting resistance mechanisms in NSCLC
  Nature Reviews Cancer, 2017
• Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
  The Lancet Oncology, 2017
• BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome
  American Journal of Kidney Diseases, 2017
• Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib
  Melanoma Research, 2015
• Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
  New England Journal of Medicine, 2012
• Fabry disease: a morphologic study of 11 cases
  Laboratory Investigation, 2006